title: Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab.
abstract: Viral infection is an important cause of morbidity and mortality in the post-allograft period. Recently, a new therapeutic approach was developed in post-transplant lymphoproliferative disorder (PTLD) induced by Epstein-Barr virus (EBV): the anti-CD20 monoclonal antibody or rituximab. We performed a single-center study on the treatment effectiveness of rituximab in three EBV-induced PTLD and evaluated biologic data, such as T and B lymphocytes count, during PTLD development and treatment. Before PTLD treatment, blood cell profile showed a severe T lymphopenia with a progressive increase of CD8+ cells and B lymphopenia. Secondly, during treatment, there appeared a T response, as in primary EBV, and a regressive B lymphopenia.
authors.affiliation: Service de Pédiatrie Onco-hématologie, CHRU Strasbourg, 67098 Strasbourg, France. Natacha.entz-werle@chru-strasbourg.fr
authors.forename: Natacha
authors.initials: N
authors.lastname: Entz-Werle
authors.forename: Nadine
authors.initials: N
authors.lastname: Cojean
authors.forename: Audrey
authors.initials: A
authors.lastname: Barats
authors.forename: Didier
authors.initials: D
authors.lastname: Eyer
authors.forename: Martine
authors.initials: M
authors.lastname: Munzer
authors.forename: Béatrice
authors.initials: B
authors.lastname: Uring-Lambert
authors.forename: Annie
authors.initials: A
authors.lastname: Falkenrodt
authors.forename: Annie
authors.initials: A
authors.lastname: Babin
authors.forename: Patrick
authors.initials: P
authors.lastname: Lutz
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes; D016026:Bone Marrow Transplantation; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes; D002648:Child; D020031:Epstein-Barr Virus Infections / Q000097:blood*; D005260:Female; D006801:Humans; D007223:Infant; D018655:Lymphocyte Count; D008232:Lymphoproliferative Disorders / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy* / Q000276:immunology*; D000069283:Rituximab; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes; D014181:Transplantation Immunology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab